Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma

Full text
Author(s):
Show less -
Ribeiro, Luciana C. [1] ; Benites, Bruno Deltreggia [2] ; Ulaf, Raisa G. [1] ; Nunes, Thyago A. [1] ; Costa-Lima, Carolina [2] ; Addas-Carvalho, Marcelo [2] ; Proenca-Modena, Jose Luiz [3, 4] ; Granja, Fabiana [4, 5] ; da Costa, Vitor Antonio [2] ; Santos Duarte, Adriana da Silva [2] ; Zangirolami, Audrey Basso [2] ; Amaro, Emerson Clayton [2] ; Mansour, Eli [1] ; Zollner, Ricardo L. [1] ; Velloso, Licio A. [1]
Total Authors: 15
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, BR-13083887 Campinas, SP - Brazil
[2] Univ Estadual Campinas, Hematol & Transfus Med Ctr, Campinas, SP - Brazil
[3] Univ Estadual Campinas, Expt Med Res Cluster EMRC, Campinas, SP - Brazil
[4] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Emerging Viruses LEVE, Campinas, SP - Brazil
[5] Univ Fed Roraima, Biodivers Res Ctr, Roraima - Brazil
Total Affiliations: 5
Document type: Journal article
Source: ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY; v. 17, n. 1 DEC 5 2021.
Web of Science Citations: 0
Abstract

Background Common variable immunodeficiency is the most prevalent symptomatic primary immunodeficiency in adults. Affected patients fail to mount an appropriate humoral response against community acquired infectious diseases and recent reports have provided data supporting the increased susceptibility of these patients to severe SARS-CoV-2 infections. In this context, the infusion of COVID-19 convalescent plasma could represent an effective therapeutic strategy. Case presentation 25-year old woman diagnosed with common variable immunodeficiency in 2013, developed severe COVID-19 that rapidly progressed to pneumonia presenting with multiple bilateral lung opacities that were both central and peripheral and presented as ground-glass and consolidation types involving all lobes, bilaterally. As blood oxygen saturation decayed and lung abnormalities were not responsive to large spectrum antibiotics and corticosteroids, patient was placed on mechanical ventilation and compassionate-use of approved COVID-19 convalescent donor plasma was introduced. The patient presented a rapid response to the approach and mechanical ventilation could be interrupted 24 h after first dose of COVID-19 convalescent donor plasma. As a whole, the patient received four doses of 200 mL convalescent plasma during a period of 6 days. There was rapid improvement of clinical status, with interruption of supplemental oxygen therapy after 6 days and reduction of lung abnormalities as evidence by sequential computed tomography scans. Conclusions This is a single patient report that adds to other few reports on common variable immunodeficiency and agammaglobulinemia, suggesting that COVID-19 convalescent donor plasma could be a valuable therapeutic approach to treat patients affected by dysgammaglobulinemias and presenting severe COVID-19. (AU)

FAPESP's process: 20/04558-0 - Characterization of intrinsic risk factors and the development of new diagnostic and treatment alternatives for COVID-19
Grantee:José Luiz Proença Módena
Support type: Regular Research Grants
FAPESP's process: 20/04522-5 - Clinical trial for bradykinin inhibition in hospitalized adults with COVID-19 grave
Grantee:Licio Augusto Velloso
Support type: Regular Research Grants
FAPESP's process: 13/07607-8 - OCRC - Obesity and Comorbidities Research Center
Grantee:Licio Augusto Velloso
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 16/00194-8 - Pathogenesis and neurovirulence of emerging viruses in Brazil
Grantee:José Luiz Proença Módena
Support type: Research Grants - Young Investigators Grants